Using genetics to predict toxicity of cancer immunotherapy

A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature Medicine 2022-12, Vol.28 (12), p.2471-2472
Hauptverfasser:	Robert, Caroline, Vagner, Stéphan, Mariette, Xavier
Format:	Artikel
Sprache:	eng
Schlagworte:	631/67/1813/1634 692/499 Arthritis Autoimmune diseases Biomarkers Biomedical and Life Sciences Biomedicine Cancer Cancer immunotherapy Cancer Research Diabetes Genetics Humans Immune checkpoint inhibitors Immune system Immunoglobulins Immunotherapy Immunotherapy - adverse effects Infectious Diseases Life Sciences Lymphocytes Medical research Medicine Melanoma Metabolic Diseases Molecular Medicine Neoplasms - genetics Neoplasms - therapy Neurosciences News & Views news-and-views Programmed Cell Death 1 Receptor Toxicity Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.
ISSN:	1078-8956 1546-170X 1744-7933
DOI:	10.1038/s41591-022-02096-4